The add-on anti-seizure therapy Inovelon (rufinamide) shows good tolerability, with one year of treatment not affecting cognitive abilities, adaptive skills, or behavior in children and adults with Lennox-Gastaut syndrome (LGS), a study from Italy reported. The study, “…
uncategorized
The Australian Therapeutic Goods Administration (TGA) has approved Epidyolex (cannabidiol) as a treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients 2 or older, according to developers GW Pharmaceuticals. In order to make Epidyolex available to Australian patients,…
Eton Pharmaceuticals has submitted a new drug application (NDA) for topiramate oral solution — an anticonvulsant formerly known as ET-101 — to the U.S. Food and Drug Administration (FDA). The NDA covers three indications: as an add-on therapy for treatment of partial-onset seizures, including…
The Scottish Medicines Council (SMC) approved Epidyolex (cannabidiol), combined with the anti-epileptic medicine clobazam, as a treatment option for children and adults with Lennox-Gastaut or Dravet Syndrome.
A European Medicines Agency (EMA) committee has recommended that the age range of Fycompa (perampanel) be expanded in the European Union (EU) to include children 4 and older with focal-onset seizures and those 7 and older with primary generalized tonic-clonic seizures (PGTCS). In the EU, Fycompa — available in…
When used alongside valproic acid, Epidiolex (cannabidiol) can increase the risk of thrombocytopenia in children and adolescents with drug-resistant forms of epilepsy, such as Lennox-Gastaut syndrome (LGS), a study shows. According to the study authors, young patients with these disorders and receiving this combination of anti-seizure medications…
Treatment with soticlestat (OV935/TAK-935) safely led to a clinically meaningful reduction in the frequency of hard-to-treat seizures in a group of children with Dravet and Lennox-Gastaut (LGS) syndromes, according to top-line data from a Phase 2 trial. Soticlestat is an experimental oral therapy…
The U.S. Food and Drug Administration (FDA) has expanded the age range of patients to whom Epidiolex (cannabidiol) can be prescribed, to include children as young as age 1, according to its developer, GW Pharmaceuticals (GW). The medication had previously been made available to patients ages 2…
The Epilepsy Foundation’s Community Day, being held virtually this year, will offer patients, caregivers, and advocates the latest information about epilepsy and an opportunity to connect with others. “Innovation and Action to End Epilepsy,” a free national conference on Aug. 29, will focus on advocacy and a variety…
Epidiolex, a cannabidiol add-on medication for treatment-resistant epilepsy, was safely given to children and teenagers for one year in a clinical trial that included youth with Lennox-Gastaut syndrome, a study reported. Seizure control was improved with no adverse treatment…
Recent
- Taking Time to Acknowledge Our Efforts as Parents and Caregivers
- Eurordis Survey: Healthcare Experience Worse for Rare Disease Patients
- Brian Is a Happy Little Man
- Pandemic Won’t Stop Rare Disease Day on Feb. 28
- I’m Ready to Embrace My Emotions as an LGS Caregiver
- International Epilepsy Day Shines Spotlight on Brain Disorder Affecting Millions
- NORD’s 6th ‘State Report Card’ Notes Progress, Raises Concerns
- Jazz Acquires GW Pharma and Epidiolex, Other Potential Cannabinoids
- Study Reveals Molecular Details of Epidiolex Action
- This Is Why I Had to Sign Off